Tags : P-III Studies

Merck & Co. Reports Results of Gefapixant (MK-7264) in Two

Shots: The two P-III studies (COUGH-1 &-2) involves assessing of gefapixant (45mg, 15mg, bid) vs PBO in 732 & 1,317 patients with refractory or unexplained chronic cough with 1EP as 24hrs. cough/hr. @12wks. and 24wks. respectively Gefapixant (45mg, bid) arm met its 1EPs i.e, decrease in 24hrs. coughs/hr. @12wks. & 24wks. while gefapixant (15mg, bid) […]Read More